Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: results of a prospective multicenter registry.
Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: results of a prospective multicenter registry.
复制标题
DOI：
10.1093/jjco/hyu128
复制
发表时间：
2014-11
影响因子：
2.4
通讯作者：
Sakata Y
中科院分区：
文献类型：
--
作者：
Satoh T;Gemma A;Kudoh S;Sakai F;Yamaguchi K;Watanabe T;Ishiguro M;Inoshiri S;Izawa M;Sugihara K;Sakata Y
我们在一项基于中心登记系统的前瞻性多中心登记研究中调查了日本结直肠癌患者接受西妥昔单抗治疗期间药物性肺损伤的发生率和临床特征。我们对2006例接受西妥昔单抗治疗的结直肠癌患者中发生或疑似发生药物性肺损伤的患者进行了调查和随访。一个由医学肿瘤学家、肺科医生和放射科医生组成的小组委员会对西妥昔单抗治疗期间发生的每例药物性肺损伤进行了评估和讨论。在登记期间确定了66例患者，并对药物性肺损伤进行了进一步检查。我们分析了发病时间、患者特征和死亡率相关因素。24例（1.2%）患者发生西妥昔单抗相关药物性肺损伤，其中15例（0.7%）患者被评为3级或更严重。14例患者接受类固醇冲击治疗。10例药物性肺损伤患者死亡，其中8例接受类固醇脉冲治疗。药物性肺损伤的发生率在老年患者和既往有间质性肺病的患者中显著较高。至发作时间无特定趋势。在开始西妥昔单抗治疗后早期发生药物性肺损伤（90天内）的患者的死亡率高于晚发患者（90天以上）。西妥昔单抗治疗患者中药物性肺损伤的发生率为1.2%。由于药物性肺损伤具有潜在的严重性，因此及时启动适当的治疗非常重要。考虑到西妥昔单抗治疗期间早发性药物性肺损伤与不良预后相关，因此必须对这些患者进行密切监测。
We investigated the incidence and clinical features of drug-induced lung injury during cetuximab therapy in Japanese patients with colorectal cancer in a prospective multicenter registry based on a central registration system. We investigated and followed up patients with or suspected of having drug-induced lung injury among 2006 patients with cetuximab-treated colorectal cancer. A subcommittee of medical oncologists, pulmonologists and a radiologist evaluated and discussed each case of drug-induced lung injury that occurred during cetuximab therapy. Sixty-six patients were identified and further examinations of drug-induced lung injury were conducted during the registration period. We analyzed time to onset, patient characteristics and factors associated with mortality. Cetuximab-related drug-induced lung injury occurred in 24 (1.2%) patients, and was rated as Grade 3 or worse in 15 (0.7%) patients. Fourteen patients received steroid pulse therapy. Ten patients with drug-induced lung injury died, of whom eight received steroid pulse therapy. The incidence of drug-induced lung injury was significantly higher in elderly patients, and in patients with prior interstitial lung disease. There was no particular trend in the time to onset. Patients with early onset of drug-induced lung injury (within 90 days) after starting cetuximab therapy had higher mortality than patients with later onset (over 90 days). The incidence of drug-induced lung injury in cetuximab-treated patients was 1.2%. Because drug-induced lung injury is potentially serious, it is important to promptly initiate appropriate treatments. Considering that early onset drug-induced lung injury during cetuximab therapy is associated with a poor prognosis, close monitoring is mandatory for these patients.
登录
查看更多内容
DOI：
10.1164/rccm.200710-1501oc
发表时间：
2008-06-15
影响因子：
24.7
作者：
Kudoh, Shoji;Kato, Harubumi;Nyberg, Fredrik
通讯作者：
Nyberg, Fredrik
DOI：
10.1164/rccm.200804-550oc
发表时间：
2008-10-01
影响因子：
24.7
作者：
Cronkhite, Jennifer T.;Xing, Chao;Garcia, Christine Kim
通讯作者：
Garcia, Christine Kim
影响因子：
5.3
作者：
Takano, T;Ohe, Y;Saijo, N
通讯作者：
Saijo, N
影响因子：
2.2
作者：
Hotta, K;Kiura, K;Tanimoto, M
通讯作者：
Tanimoto, M
影响因子：
158.5
作者：
Jonker, Derek J.;O'Callaghan, Chris J.;Moore, Malcolm J.
通讯作者：
Moore, Malcolm J.